X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA LUPIN LTD ALEMBIC PHARMA/
LUPIN LTD
 
P/E (TTM) x 26.6 16.6 160.5% View Chart
P/BV x 6.1 3.9 157.2% View Chart
Dividend Yield % 0.8 0.8 97.3%  

Financials

 ALEMBIC PHARMA   LUPIN LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
LUPIN LTD
Mar-16
ALEMBIC PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs7922,127 37.2%   
Low Rs4431,294 34.2%   
Sales per share (Unadj.) Rs167.0304.1 54.9%  
Earnings per share (Unadj.) Rs38.250.4 75.7%  
Cash flow per share (Unadj.) Rs42.060.7 69.2%  
Dividends per share (Unadj.) Rs4.007.50 53.3%  
Dividend yield (eoy) %0.60.4 147.8%  
Book value per share (Unadj.) Rs84.9243.8 34.8%  
Shares outstanding (eoy) m188.52450.58 41.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.75.6 65.7%   
Avg P/E ratio x16.233.9 47.7%  
P/CF ratio (eoy) x14.728.2 52.2%  
Price / Book Value ratio x7.37.0 103.6%  
Dividend payout %10.514.9 70.4%   
Avg Mkt Cap Rs m116,383770,740 15.1%   
No. of employees `000NA16.4 0.0%   
Total wages/salary Rs m4,21421,077 20.0%   
Avg. sales/employee Rs ThNM8,379.6-  
Avg. wages/employee Rs ThNM1,289.0-  
Avg. net profit/employee Rs ThNM1,388.7-  
INCOME DATA
Net Sales Rs m31,487137,016 23.0%  
Other income Rs m551,877 2.9%   
Total revenues Rs m31,542138,893 22.7%   
Gross profit Rs m10,06037,535 26.8%  
Depreciation Rs m7224,635 15.6%   
Interest Rs m37446 8.2%   
Profit before tax Rs m9,35634,330 27.3%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,16011,536 18.7%   
Profit after tax Rs m7,19422,707 31.7%  
Gross profit margin %31.927.4 116.6%  
Effective tax rate %23.133.6 68.7%   
Net profit margin %22.816.6 137.9%  
BALANCE SHEET DATA
Current assets Rs m15,06697,790 15.4%   
Current liabilities Rs m7,67453,872 14.2%   
Net working cap to sales %23.532.1 73.2%  
Current ratio x2.01.8 108.1%  
Inventory Days Days6785 79.1%  
Debtors Days Days41121 33.5%  
Net fixed assets Rs m8,23786,379 9.5%   
Share capital Rs m377901 41.8%   
"Free" reserves Rs m15,416105,735 14.6%   
Net worth Rs m16,005109,844 14.6%   
Long term debt Rs m053,739 0.0%   
Total assets Rs m24,594224,378 11.0%  
Interest coverage x255.277.9 327.5%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.6 209.7%   
Return on assets %29.410.3 284.9%  
Return on equity %44.920.7 217.4%  
Return on capital %58.721.2 276.7%  
Exports to sales %55.749.1 113.6%   
Imports to sales %10.47.4 140.1%   
Exports (fob) Rs m17,55167,244 26.1%   
Imports (cif) Rs m3,28310,199 32.2%   
Fx inflow Rs m17,81171,405 24.9%   
Fx outflow Rs m5,31817,807 29.9%   
Net fx Rs m12,49353,598 23.3%   
CASH FLOW
From Operations Rs m9,304-3,690 -252.2%  
From Investments Rs m-3,105-69,434 4.5%  
From Financial Activity Rs m-1,95958,126 -3.4%  
Net Cashflow Rs m4,240-14,998 -28.3%  

Share Holding

Indian Promoters % 74.1 46.6 159.0%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 2.9 11.3 25.7%  
FIIs % 9.1 31.9 28.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.1 137.6%  
Shareholders   49,328 98,259 50.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALEMBIC LTD  AUROBINDO PHARMA  IPCA LABS  FDC LTD.  SUN PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS